Abstract
Background Few head-to-head comparisons have been performed on the real-world effectiveness of COVID-19 booster vaccines. We evaluated the relative effectiveness (rVE) of a primary series of mRNA-1273 versus BNT162b2 and Ad26.COV2.S and a homologous mRNA booster against medically-attended, outpatient, and hospitalized COVID-19.
Methods A dataset linking primary care electronic medical records with medical claims data was used for this retrospective cohort study of US patients ≥18 years vaccinated with a primary series between February and October 2021 (Part 1) and a homologous mRNA booster between October 2021 and January 2022 (Part 2). Adjusted hazard ratios (HR) were derived from 1:1 matching adjusted across potential covariates. rVE was (1-HRadjusted) x 100. Additional analysis was performed across regions and age groups.
Results Following adjustment, Part 1 rVE for mRNA-1273 versus BNT162b2 was 23% (95% CI: 22%–25%), 23% (22%–25%), and 19% (14%–24%) whilst the rVE for mRNA-1273 versus Ad26.COV2.S was 50% (48%–51%), 50% (48%–52%), and 57% (53%–61%) against any medically-attended, outpatient, and hospitalized COVID-19, respectively. The adjusted rVE in Part 2 for mRNA-1273 versus BNT162b2 was 14% (10%–18%), 13% (8%– 17%), and 19% (1%–34%) against any medically-attended, outpatient, and hospitalized COVID-19, respectively. rVE against medically-attended COVID-19 was higher in adults ≥65 years (35%; 24%–47%) than those 18–64 years (13%; 9%–17%) after the booster.
Conclusions In this study, mRNA-1273 was more effective than BNT162b2 or Ad26.COV2.S following primary series during a Delta-dominant period, and than BNT162b2 as a booster during an Omicron-dominant period.
Key points mRNA-1273 was associated with a lower risk than BNT162b2 or Ad26.COV2.S of any medically-attended, outpatient, or hospitalized COVID-19 after primary series and of any medically-attended, outpatient, or hospitalized COVID-19 vs BNT162b2 after a homologous mRNA booster
Competing Interest Statement
JAM, NVV, DE, PB, DM, and AR are employees of and shareholders in Moderna, Inc. AB, MS, and MB work for Veradigm, VHN, CB, and TD are employees of VHN Consulting. Both companies were contracted by Moderna and received fees for data management and statistical analyses.
Funding Statement
This work was supported by Moderna Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
As a noninterventional, retrospective database study using a certified Health Insurance Portability and Accountability Act-compliant deidentified research database, approval by an institutional review board was not necessary.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Individual-level data reported in this study are not publicly shared. Upon request, and subject to review, Veradigm may provide the de-identified aggregate-level data that support the findings of this study. Deidentified data (including participant data as applicable) may be shared upon approval of an analysis proposal and a signed data access agreement. Individual-level data reported in this study are not shared publicly but they are shared fully with regulatory agencies.
